Tag Archive for: HRR
ATRN-119: A New Promising ATR Inhibitor for ATM Mutations (And Other HRR Mutations)
/0 Comments/in Not PCa related/by MaxAMPLITUDE Trial Update: Niraparib Plus Abiraterone Shows Promise for HRR-Altered Metastatic Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxTALAPRO-2 Trial: Final Results Update For HRR Mutations (BRCA, ATM,…)
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 1 trial: SYN818 Shows Promise for Prostate Cancer Patients With HRR Genetic Mutations
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxTalazoparib Plus Enzalutamide in HRR-Deficient mCRPC: Final Overall Survival Results from TALAPRO-2
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxASCO GU 2025: Impact of Homologous Recombination Repair Alterations on Survival Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (BRCA, ATM, CDK12,…)
/0 Comments/in Observational, Retrospective studies/by MaxTargeting LIG1 with PARP Inhibitors: E New Target Identified Using CRISPR
/0 Comments/in CRISPR, PARPi, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA MYC NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor personalized medicine Pluvicto prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- UPDATE: INKmune CaRe Trial Phase 1 Results August 5, 2025
- Newsletter 31/2025 August 3, 2025
- Preclinical Advances in Sequencing CDK4/6 and PARP Inhibitors August 2, 2025
- UPDATE 2: More Data About ATNM-400 Antibody Radioconjugate Therapy August 1, 2025